Susavion Biosciences, Inc., is a privately-owned, pre-clinical stage biotechnology company that was founded to develop immunotherapeutic drugs suitable for a global market. Susavion’s technology is based on a novel platform—peptide mimetics of sugar-containing molecules—that are ligands of strategic regulatory receptors on immune cells. The technology unleashes the power of the human immune system to reset signals sent from dysfunctional disease states. Susavion’s drugs are potent stimulators of cell-mediated and humoral immunotherapy to overcome the ability of cancer cells to escape. Most importantly, they do not have the toxic effects that accompany chemo-therapy drugs and other immune therapies. Our drugs have broad application against cancers, have low toxicity, low cost, and thus are potential game changers. Susavion’s lead drug has demonstrated proof-of-concept in oncology studies, in particular suppression of accumulation of ascites associated with ovarian cancer, extended survival of mice with implanted glioma cells, and reduced immunosuppressive regulatory T cells in melanoma tumors.